PMGC Holdings Inc.

ELAB

NASDAQHealthcareBiotechnology

在 GoAI 中打开

前收盘价

US$6.66

+US$0.56 · +9.18%

8月21日 16:00 ET

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

31/ 100

GoAI评分

Sell

Trim exposure — unfavorable risk-reward

估值

Expensive

动量

Weakening

情绪

Mixed

风险韧性

High Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Graydon Bensler
上市以来: 2023年11月21日
雇员: 33